Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of CAEL-101 plus plasma cell dyscrasia therapy versus placebo plus plasma cell dyscrasia therapy in treatment-naive Mayo stage IIIa AL amyloidosis
CTR20230778Phase 3Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of anselamimab in light-chain amyloidosis, sponsored by Alexion Pharmaceuticals. Started May 2023; status: active.
02
Drugs
anselamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on CTR20230778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230778.